Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442896 · ClinicalTrials.gov registry record
STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
A clinical trial, sponsored by University of California, San Diego.
- Completed
- Registry status
- 133
- Enrollment target
NCT01442896: Completed study, sponsored by University of California, San Diego.
NCT01442896 is a clinical trial that has completed, run by University of California, San Diego. The registered enrollment target is 133 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01442896 has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to perform exploratory analyses to evaluate rates of functional and structural change in glaucoma, to identify predictors of rapid progression in patients with glaucoma and to identify possible genetic factors and biomarkers associated with the disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2011-09-01 |
| Est. Completion | 2015-12-18 |
What the finished NCT01442896 record still lists
NCT01442896 is an observational study that tracks outcomes without assigning an intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01442896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01442896 about?
NCT01442896 is a clinical study titled "STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk". The purpose of this study is to perform exploratory analyses to evaluate rates of functional and structural change in glaucoma, to identify predictors of rapid progression in patients with glaucoma and to identify possible genetic factors and biomarkers associated with the disease.
What is the current status of trial NCT01442896?
This trial is currently completed. The enrollment target is 133 participants. The study started on 2011-09-01. Estimated completion is 2015-12-18.
Who is sponsoring clinical trial NCT01442896?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI